Avid Bioservices Inc (CDMO)

[Protector]

RRDog, thanks for this down to Earth and very clear post.

We may not agree on PPHM dilution but we don't have to. But we certainly agree an many other things among whom the general philosophy that reaching the end-goal is more important then small time or strategy changes along the road. I would personally find it miraculous if a company in biotech that depends on so many 3rd party events and participation, from centres over Doctors to patients, would be able to plan things TOPS on the week or mount.

And as a general sentiment, or lets maybe just make that a personal sentiment, I have the feeling a new 'dynamic' is with PPHM since the last quarterly and the MSK/AstraZeneca deals as if there is some awakening going on. I am interested to see if the new PR company progresses as you hope. We have no idea how far their mandate goes, but it is no secret that PPHM still has some distance to cover to come to good communication and promotion. You once wrote "this can be learned" (or something along those lines) on the subject. Well I find, from the last public appearances, that our CEO improved and of course that letting Worsley and Brekken speak certainly adds to the quality of communication. I am a Dr. Brekken fan but I think that is no secret and CERTAINLY doesn't mean I do not appreciate the work of other great PPHM minds such as Dr. Garnick and of course late Dr. Thorpe without whom we wouldn't probably be here.

As to Dr. Birge (Rutger's) and Dr. Wolchok (MSK). Those people HAVE a reputation. It is normal that they move slowly but surely because they are always working on the EDGE of new science in undiscovered area's where the risk for error and failure is bigger. They have MUCH to loose with wrong positions because they will follow them for the rest of their careers. Hence I think this is partial substantiation for one of massH's statements about some things that cannot be bought or paid for. Exactly that fact makes it so valuable if such people do speak about and endorse Bavituximab.

By being presents on PPHM's Friday evening event Birge actually made some implicit connection between PS-Targeting and Bavituximab in global immune checkpoint applications. Actually he presented the 'global' aspect and Brekken connected PS to Bavituximab. Ofcourse even better if indeed Brige names Bavituximab loud and clear.

And Wolchok, by letting him, or at least his team if we are not sure he was part of it, be entertained on the PPHM booth has also shown that PPHM isn't just a name on a list of MSK sponsoring collaborators who expect nothing more then name association with MSK and Wolchok's lab. He could get entertained on ANY BOOTH of his choice, even the very big ones since he has disclosed links with AstraZeneca, Roche, BMY and Merck. But yes, to the public and certainly Wall Street, him taking a favourable position or linking Bavituximab in a combo strategy would certainly not pass unnoticed. Possibly that are those catalysts that are on NO LIST because they resort of the category of surprise. We'll see.

#prayforparis